KB Homes Down, Arm to Sell Its Own Chips, ImmunityBio Plunges

Stock Movers

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:

- KB Home (KBH) shares are down 5% in postmarket trading Tuesday after the single-family home builder reported forecast deliveries for the second quarter that missed the average analyst estimate.

- Arm Holdings (ARM) which made its name licensing technology to semiconductor makers, will begin selling its own chips for the first time, adding a business that it expects to generate about $15 billion annually within five years. Shares closed down 1.41%.

- ImmunityBio (IBRX)shares plunged after the biotechnology company and its billionaire executive chairman, Patrick Soon-Shiong, were hit with a Food and Drug Administration warning letter for false and misleading promotion of its bladder cancer drug Anktiva.

See omnystudio.com/listener for privacy information.

More description

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:

- KB Home (KBH) shares are down 5% in postmarket trading Tuesday after the single-family home builder reported forecast deliveries for the second quarter that missed the average analyst estimate.

- Arm Holdings (ARM) which made its name licensing technology to semiconductor makers, will begin selling its own chips for the first time, adding a business that it expects to generate about $15 billion annually within five years. Shares closed down 1.41%.

- ImmunityBio (IBRX)shares plunged after the biotechnology company and its billionaire executive chairman, Patrick Soon-Shiong, were hit with a Food and Drug Administration warning letter for false and misleading promotion of its bladder cancer drug Anktiva.

See omnystudio.com/listener for privacy information.

2026-03-24 3 min Transcript
Listen elsewhere

Available Results

Generated results are saved to your library for reuse and search.

No generated results are available for this episode yet.

Transcript

Open the Transcript tab to load the transcript.

Chapters

No chapters available.